How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

574 results for

Malaria Chemoprophylaxis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Point-of-care tests for malaria

Point-of-care tests for malaria NIHR Diagnostic Evidence Cooperative Oxford www.oxford.dec.nihr.ac.uk Diagnostic Evidence Co-operative Oxford Cooperative Oxford HR Diagnostics Evidence Cooperative Oxford Clinical Question: In the primary care setting, what is the accuracy and utility of malaria point-of-care (POC) tests in the detection of parasitaemia caused by Plasmodium species, compared to standard laboratory practice using Microscopy and/or Polymerase Chain Reaction (PCR)? Background (...) , Current Practice and Advantages over Existing Technology: Background: Malaria is an important infectious disease, caused by the protozoan Plasmodium and transmitted by inoculation with an infected Anopheles mosquito. A variety of Plasmodium species cause malaria, typically producing cyclical systemic symptoms including fever, headache, vomiting and lethargy. Infection with Plasmodium falciparum can result in severe disease, and can lead to neurological sequelae including cerebral malaria and at worst

2015 Publication 4878904

42. Strategies to Increase the Ownership and Use of Insecticide?Treated Bednets to Prevent Malaria Full Text available with Trip Pro

). 3.2 SEARCH METHODS FOR IDENTIFICATION OF STUDIES The initial search was conducted in May 2011. Updates of the initial search were conducted in March 2012 and February 2013. Search results are reported in a PRISMA flow diagram ( ) ( ). The EPOC Trials Search Coordinator developed search strategies (Appendix 1) in consultation with the authors. They comprise keywords and controlled vocabulary terms for malaria or parasites causing malaria in humans (Plasmodium falciparum/malariae/ovale/vivax (...) Strategies to Increase the Ownership and Use of Insecticide?Treated Bednets to Prevent Malaria Strategies to Increase the Ownership and Use of Insecticide‐Treated Bednets to Prevent Malaria - Polec - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Strategies to Increase the Ownership and Use of Insecticide‐Treated Bednets

2015 Campbell Collaboration

43. Grammomys surdaster, the Natural Host for Plasmodium berghei Parasites, as a Model to Study Whole-Organism Vaccines against Malaria. Full Text available with Trip Pro

Grammomys surdaster, the Natural Host for Plasmodium berghei Parasites, as a Model to Study Whole-Organism Vaccines against Malaria. AbstractInbred mice are commonly used to test candidate malaria vaccines, but have been unreliable for predicting efficacy in humans. To establish a more rigorous animal model, we acquired African woodland thicket rats of the genus Grammomys, the natural hosts for Plasmodium berghei. Thicket rats were acquired and identified as Grammomys surdaster by skull (...) -organism vaccines to induce sterile immunity, and compared the thicket rat model to conventional mouse models. Using P. berghei ANKA radiation-attenuated sporozoites, and P. berghei ANKA and P. yoelii chemoprophylaxis vaccination approaches, we found that standard doses of vaccine sufficient to protect laboratory mice for a long duration against malaria challenge, are insufficient to protect thicket rats, which require higher doses of vaccine to achieve even short-term sterile immunity. Thicket rats

2017 American Journal of Tropical Medicine & Hygiene

44. Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

-malarial drugs. Outcome Measures Go to Primary Outcome Measures : Number of subjects with Plasmodium falciparum (P.falciparum) parasitemia (defined by a positive blood slide) [ Time Frame: 28 days after sporozoite challenge (at Day 314) ] The analysis aims at comparing RTS,S/AS01B administered as full doses at Month 0 and Month 1 and 1/5th dose at Month 7 (AduFx group) versus infectivity controls. Number of subjects with P. falciparum parasitemia (defined by a positive blood slide) [ Time Frame: 28 (...) has been or will be exposed to an investigational or a non-investigational vaccine/product. Seropositive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV). Documented HIV-positive subject. Previous vaccination against malaria. History of malaria chemoprophylaxis within 60 days prior to vaccination. Any history of malaria (for the vaccine groups). Planned travel to malaria endemic areas during the study period. History of splenectomy. Any confirmed or suspected immunosuppressive

2017 Clinical Trials

45. Failure of malaria chemoprophylaxis with mefloquine in an oversize traveller to Mozambique. Full Text available with Trip Pro

Failure of malaria chemoprophylaxis with mefloquine in an oversize traveller to Mozambique. A case of failure of mefloquine prophylaxis in an oversize traveller, who correctly took the drug. This case seems to be attributed to mefloquine resistance, however it is suggested that mefloquine dosage should be modulated by body weight, as is already indicated by some authorities.

2013 Malaria journal

46. Towards improved uptake of malaria chemoprophylaxis among West African travellers: identification of behavioural determinants. Full Text available with Trip Pro

Towards improved uptake of malaria chemoprophylaxis among West African travellers: identification of behavioural determinants. Malaria is a potentially lethal illness for which preventive measures are not optimally used among all travellers. Travellers visiting friends and relatives in their country of origin (VFRs) are known to use chemoprophylaxis less consistently compared to tourist travellers. In this study, factors explaining the low use of chemoprophylaxis were pursued to contribute (...) travelling to West Africa had not started chemoprophylaxis; therefore, there is room for improvement. Risk reduction strategies could aim at improving attendance to travel clinics and focus on young-, business and long term travellers and VFRs who have experienced malaria during consultation. Risk reduction strategies should focus on improving self-efficacy and conceptions of response efficacy, including social environment to aim at creating the positive social context needed.

2013 Malaria journal

47. Adult Malaria Chemoprophylaxis Prescribing Patterns in the Military Health System from 2007-2011. Full Text available with Trip Pro

Adult Malaria Chemoprophylaxis Prescribing Patterns in the Military Health System from 2007-2011. The Military Health System (MHS), with 9.7 million beneficiaries, represents an enormous pool of potential travelers requiring malaria prevention measures. A systematic search of the MHS electronic pharmacy record was performed for prescriptions of atovaquone-proguanil (AP), chloroquine (CQ), doxycycline (DC), mefloquine (MQ), primaquine (PQ) to adult patients from 2007 through 2011. Over 1,000,000

2013 American Journal of Tropical Medicine & Hygiene

48. Malaria prophylaxis

) and chemoprophylaxis. Causal chemoprophylaxis (for example primaquine) works by inhibiting the pre-erythrocytic (liver) phase of the malaria parasite lifecycle. Suppressive chemoprophylaxis (for example chloroquine, doxycycline, proguanil, and mefloquine) kills the asexual blood stages of the malaria parasite. [ ; ; ; ; ; ; ; ; ; ; ; ; ; ] Causes What causes malaria? Malaria is caused by infection with the protozoan parasite Plasmodium. Species of Plasmodium that are known to cause malaria in humans include: P (...) for malaria deaths in travellers [ ] found that the main risk factors were: Non-use or inappropriate use of chemoprophylaxis. Older age. Male sex. Delay in seeking care. Delay in diagnosis. Incorrect treatment. Infection with P. falciparum . Non-immunity — people born in countries where malaria is endemic may have some immunity to malaria infection from continual exposure to the parasite. Immunity rapidly declines when exposure to Plasmodium stops for example when a person moves from an endemic to non

2018 NICE Clinical Knowledge Summaries

49. Summary of recommendations for the prevention of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT)

a malarious region: a prospective study. Soc Sci Med 1999;48(11):1641-54. Footnote 23 Queyriaux B, Texier G, Ollivier L, Galoisy-Guibal L, Michel R, Meynard JB, et al. Plasmodium vivax malaria among military personnel, French Guiana, 1998-2008. Emerg Infect Dis 2011 Jul;17(7):1280-1282. Footnote 24 Kain KC, MacPherson DW, Kelton T, Keystone JS, Mendelson J, MacLean JD. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ 2001 Mar;164(5):654-659. Footnote 25 Landry P (...) de santé). 2011; Available at: http://opac.invs.sante.fr/doc_num.php?explnum_id=7068. (not available in English) Accessed June 1, 2011. Appendix Top 25 countries for malaria risk and recommended chemoprophylaxis (6,60-66) Country Malaria transmission area Chemoprophylaxis recommended by CATMAT Season Plasmodium falciparum (%) 1 Uganda All areas ATQ-PG, DOXY or MFQ Year-round > 85 2 Ghana All areas ATQ-PG, DOXY or MFQ Year-round > 90 3 Democratic Republic of Congo All areas ATQ-PG, DOXY or MFQ

2014 CPG Infobase

50. Summary of recommendations for the diagnosis and treatment of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT)

all major sources of information on malaria diagnosis and treatment, as well as recent research and national and international epidemiological data, to tailor guidelines to the Canadian context. The evidence-based medicine recommendations were developed with associated rating scales for the strength and quality of the evidence. Recommendations: Malarial management depends on rapid identification of the disease, as well as identification of the malaria species and level of parasitemia. Microscopic (...) or complicated malaria requires admission to hospital for regular monitoring of respiratory rate and pattern, coma score, and glucose and urine output, especially if the patient is unconscious. In high levels of parasitemia, exchange transfusion may be beneficial to remove infected red blood cells and toxic mediators from the circulation, and reduce the parasite load . Because of the elevated risk of severe or complicated malaria, those with a diagnosis of Plasmodium falciparum malaria should also

2014 CPG Infobase

51. Amplification of GTP-cyclohydrolase 1 gene in Plasmodium falciparum isolates with the quadruple mutant of dihydrofolate reductase and dihydropteroate synthase genes in Ghana. Full Text available with Trip Pro

Amplification of GTP-cyclohydrolase 1 gene in Plasmodium falciparum isolates with the quadruple mutant of dihydrofolate reductase and dihydropteroate synthase genes in Ghana. Sulfadoxine-pyrimethamine (SP) is used as malaria chemoprophylaxis for pregnant women and children in Ghana. Plasmodium falciparum resistance to SP is linked to mutations in the dihydropteroate synthase gene (pfdhps), dihydrofolate reductase gene (pfdhfr) and amplification of GTP cyclohydrolase 1 (pfgch1) gene. The pfgch1 (...) with SP resistance in the country. Policy makers need to begin the search for a replacement chemoprophylaxis drug for malaria vulnerable groups in Ghana.

2018 PLoS ONE

52. Management of Plasmodium vivax risk and illness in travelers Full Text available with Trip Pro

Management of Plasmodium vivax risk and illness in travelers Malaria poses an exceptionally complex problem for providers of travel medicine services. Perceived high risk of exposure during travel typically prompts prescribing protective antimalarial drugs. Suppressive chemoprophylactic agents have dominated strategy for that practice for over 70 years. This broad class of therapeutic agents kills parasites after they emerge from the liver and attempt development in red blood cells (...) . The dominance of suppressive chemoprophylaxis in travel medicine stems largely from the view of Plasmodium falciparum as the utmost threat to the patient - these drugs are poorly suited to preventing Plasmodium vivax and Plasmodium ovale due to inactivity against the latent liver stages of these species not produced by P. falciparum. Those hypnozoites awaken to cause multiple clinical attacks called relapses in the months following infection. Causal prophylactic agents kill parasites as they attempt

2017 Tropical diseases, travel medicine and vaccines

53. Malaria Chemoprophylaxis

Malaria Chemoprophylaxis Malaria Chemoprophylaxis Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Malaria Chemoprophylaxis Malaria (...) Chemoprophylaxis Aka: Malaria Chemoprophylaxis , Malaria Prophylaxis From Related Chapters II. Precautions Malaria Prophylaxis taken exactly as prescribed does not ensure complete protection may still occur at 1 week to 1 year after infection may also recur after completing treatment III. Protocol Always check CDC for resistance before prescribing CDC Travelers Health for regional recommendations Chemoprophylaxis is for prevention only Dosing below does not apply to treatment Chemoprophylaxis Schedule Agents

2015 FP Notebook

54. Guidelines for the treatment of malaria. Third edition

@who.intContents 1 | Introduction 15 2 | Clinical malaria and epidemiology 23 3 | Diagnosis of malaria 27 4 | Treatment of uncomplicated Plasmodium falciparum malaria 31 5 | Treatment of uncomplicated P. falciparum malaria in special Risk Groups 47 6 | Treatment of uncomplicated malaria caused by P. vivax, P. ovale, P. malariae or P. knowlesi 59 7 | Treatment of severe malaria 71 8 | Management of malaria cases in special situations 89 9 | Artemisinin-based combination therapies not currently recommended (...) Assessment, Development and Evaluation (GRADE) for assessing the quality of evidence 145 Annex 5 | Pharmacology of antimalarial drugs 205 Annex 6 | T reatment o f Plasmodium vivax, P. ovale, P. malariae and P. knowlesi infections 285 Annex 7 | Resistance to antimalarial medicines 299Glossary Artemisinin-based combination therapy (ACT). A combination of an artemisinin derivative with a longer-acting antimalarial that has a different mode of action. Asexual cycle. The life cycle of the malaria parasite

2015 World Health Organisation Guidelines

55. <i>Plasmodium falciparum</i> kelch propeller polymorphisms in clinical isolates from Ghana: 2007-2016. Full Text available with Trip Pro

Plasmodium falciparum kelch propeller polymorphisms in clinical isolates from Ghana: 2007-2016. The continuous surveillance of polymorphisms in the kelch propeller domain of Plasmodium falciparum from Africa is important for the discovery of the actual markers of artemisinin resistance in the region. The information on the markers is crucial for control strategies involving chemotherapy and chemoprophylaxis for residents and non-immune travellers to the country. Polymorphisms (...) in the kelch propeller domain of Ghanaian malaria parasites from three different ecological zones at several time periods were assessed. A total of 854 archived samples (2007-2016) collected from uncomplicated malaria patients aged ≤9 years old from 10 sentinel sites were used. Eighty-four percent had wildtype sequences (PF3D7_1343700) while many of the mutants had mostly nonsynonymous mutations clustered around codons 404-650. Variants with different amino acid changes of the codons associated with ART

2019 Antimicrobial Agents and Chemotherapy

56. Imported cases of malaria in Spain: observational study using nationally reported statistics and surveillance data, 2002-2015. Full Text available with Trip Pro

species (Plasmodium falciparum). The main place of infection was Africa (88.9%), particularly Equatorial Guinea (33.2%). Most reported cases were visiting friends and relatives (VFRs) and immigrants (70.2%). A significant increased likelihood of hospitalization was observed for children under 10 years (aOR:2.7; 95% CI 1.9-3.9), those infected by Plasmodium vivax (4.3; 95% CI 2.1-8.7) and travellers VFRs (1.4; 95% CI 1.1-1.7). Only 4% of cases reported a correct regime of chemoprophylaxis. Being male (...) Imported cases of malaria in Spain: observational study using nationally reported statistics and surveillance data, 2002-2015. Malaria was eliminated in Spain in 1964. Since then, more than 10,000 cases of malaria have been reported, mostly in travellers and migrants, making it the most frequently imported disease into this country. In order to improve knowledge on imported malaria cases characteristics, the two main malaria data sources were assessed: the national surveillance system

2019 Malaria journal

57. Examining community perceptions of malaria to inform elimination efforts in Southern Mozambique: a qualitative study. Full Text available with Trip Pro

to health facilities, and lack of transportation.Several constraints and opportunities will potentially influence malaria elimination in Magude. Malaria awareness, trust in health institutions, and the demand for chemoprophylaxis could facilitate new interventions, such as mass drug administration. A lack of awareness of asymptomatic carriers, inadequate understanding of residual transmission, and barriers to care seeking could jeopardize uptake. Hence, elimination campaigns require strong community (...) Examining community perceptions of malaria to inform elimination efforts in Southern Mozambique: a qualitative study. In a background of renewed calls for malaria eradication, several endemic countries in sub-Saharan Africa are contemplating malaria elimination nationally or sub-nationally. In Mozambique, a strategy to eliminate malaria in the south is underway in the context of low endemicity levels and cross-border initiatives to eliminate malaria in South Africa and Eswatini. In this context

2019 Malaria journal

58. Barriers to malaria prevention in US-based travelers visiting friends and relatives abroad: A qualitative study of West African immigrant travelers. Full Text available with Trip Pro

of statements.Participants described the high cost of provider visits and chemoprophylaxis, challenges in advocating for themselves in healthcare settings and concerns about offending or inconveniencing hosts as barriers to malaria prevention. Cultural barriers to accessing pre-travel care included competing priorities when trip planning, such as purchasing gifts for family, travel logistics and safety concerns. When participants sought pre-travel care, most consulted their primary care provider. Participants expressed (...) Barriers to malaria prevention in US-based travelers visiting friends and relatives abroad: A qualitative study of West African immigrant travelers. Over half of malaria cases reported in the USA occur among people travelling to visit friends and relatives (VFRs), predominantly to West Africa. Few studies have queried VFR travellers directly on barriers to seeking pre-travel care. We aim to describe the knowledge, attitudes and practices of VFRs travelling to malaria-endemic countries from

2019 Journal of Travel Medicine

59. Chemotherapy and Chemoprophylaxis of Malaria Full Text available with Trip Pro

Chemotherapy and Chemoprophylaxis of Malaria 14904985 2004 02 15 2018 12 01 0007-1447 1 4758 1952 Mar 15 British medical journal Br Med J Chemotherapy and chemoprophylaxis of malaria; clinical trials in 500 cases and mass prophylaxis in a hyperendemic area. 568-74 CHAUDHURI R N RN CHAKRAVARTY N K NK RAI CHAUDHURI M N MN JANARDAN POTI S S eng Journal Article England Br Med J 0372673 0007-1447 OM Chemoprevention Humans Malaria therapy 5221:35569:224 MALARIA/therapy 1952 3 15 1952 3 15 0 1 1952 3

1952 British medical journal

60. Chemoprophylaxis for Malaria Full Text available with Trip Pro

Chemoprophylaxis for Malaria 18730679 2010 06 28 2010 06 28 0008-1264 116 2 1972 Feb California medicine Calif Med Chemoprophylaxis for malaria. 51-2 Chin J J eng Journal Article United States Calif Med 0410260 0008-1264 1972 2 1 0 0 1972 2 1 0 1 1972 2 1 0 0 ppublish 18730679 PMC1518218

1972 California Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>